{"doi":"10.1200/jco.22.01815","title":"Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group","abstract":"PURPOSE: Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to determine if the addition of the IGF-1R monoclonal antibody ganitumab to interval-compressed chemotherapy improves event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma. METHODS: Patients were randomly assigned 1:1 at enrollment to standard arm (interval-compressed vincristine/doxorubicin/cyclophosphamide alternating once every 2 weeks with ifosfamide/etoposide = VDC/IE) or to experimental arm (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy). A planned sample size of 300 patients was projected to provide 81% power to detect an EFS hazard ratio of 0.67 or smaller for the experimental arm compared with the standard arm with a one-sided α of .025. RESULTS: = .50). The 3-year overall survival estimates were 59.5% (95% CI, 50.8 to 67.3) for the standard arm and 56.7% (95% CI, 48.3 to 64.2) for the experimental arm. More cases of pneumonitis after radiation involving thoracic fields and nominally higher rates of febrile neutropenia and ALT elevation were reported on the experimental arm. CONCLUSION: Ganitumab added to interval-compressed chemotherapy did not significantly reduce the risk of EFS event in patients with newly diagnosed metastatic Ewing sarcoma, with outcomes similar to prior trials without IGF-1R inhibition or interval compression. The addition of ganitumab may be associated with increased toxicity.","journal":"Journal of Clinical Oncology","year":2023,"id":316879,"datarank":1.7080977108814765,"base_score":4.499809670330265,"endowment":4.499809670330265,"self_citation_contribution":0.6749714505495399,"citation_network_contribution":1.0331262603319367,"self_endowment_contribution":0.6749714505495399,"citer_contribution":1.0331262603319367,"corpus_percentile":null,"corpus_rank":null,"citation_count":89,"citer_count":74,"citers_with_citation_signal":46,"citers_with_endowment":46,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.955,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02306161"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":413360,"name":"Mark Krailo","orcid":"0000-0002-7608-0698","position":1,"is_corresponding":false},{"id":292436,"name":"Julia Glade Bender","orcid":"0000-0001-5316-6440","position":2,"is_corresponding":false},{"id":555347,"name":"Allen Buxton","orcid":null,"position":3,"is_corresponding":false},{"id":322326,"name":"Nadia N. Laack","orcid":"0000-0002-4385-6349","position":4,"is_corresponding":false},{"id":411468,"name":"R. Lor Randall","orcid":"0000-0002-3660-774X","position":5,"is_corresponding":false},{"id":290358,"name":"Helen X. Chen","orcid":null,"position":6,"is_corresponding":false},{"id":581523,"name":"Nita L. Seibel","orcid":"0000-0001-6259-7955","position":7,"is_corresponding":false},{"id":1022017,"name":"Matthew Boron","orcid":null,"position":8,"is_corresponding":false},{"id":985838,"name":"Stephanie Terezakis","orcid":"0000-0002-8125-3987","position":9,"is_corresponding":false},{"id":800807,"name":"Christine E. Hill‐Kayser","orcid":"0000-0002-1993-1185","position":10,"is_corresponding":false},{"id":926302,"name":"Andrea Hayes","orcid":null,"position":11,"is_corresponding":false},{"id":232647,"name":"Joel M. Reid","orcid":"0000-0003-2872-3123","position":12,"is_corresponding":false},{"id":493200,"name":"Lisa A. Teot","orcid":null,"position":13,"is_corresponding":false},{"id":376335,"name":"Dinesh Rakheja","orcid":"0000-0001-6888-7902","position":14,"is_corresponding":false},{"id":564633,"name":"Richard B. Womer","orcid":"0000-0002-4405-1200","position":15,"is_corresponding":false},{"id":386587,"name":"Carola Arndt","orcid":null,"position":16,"is_corresponding":false},{"id":465978,"name":"Stephen L. Lessnick","orcid":"0000-0001-9645-4434","position":17,"is_corresponding":false},{"id":570225,"name":"Brian D. Crompton","orcid":"0000-0001-9404-6621","position":18,"is_corresponding":false},{"id":417605,"name":"E. Anders Kolb","orcid":"0000-0003-2854-9014","position":19,"is_corresponding":false},{"id":614984,"name":"Heike E. Daldrup‐Link","orcid":"0000-0002-4929-819X","position":20,"is_corresponding":false},{"id":1022018,"name":"Eric P. Eutsler","orcid":null,"position":21,"is_corresponding":false},{"id":244422,"name":"Damon R. Reed","orcid":"0000-0002-8238-2465","position":22,"is_corresponding":false},{"id":346979,"name":"Katherine A. Janeway","orcid":"0000-0001-6000-3594","position":23,"is_corresponding":false},{"id":398284,"name":"Richard Görlick","orcid":"0000-0001-8995-2929","position":24,"is_corresponding":false},{"id":305844,"name":"Steven G. DuBois","orcid":"0000-0003-0882-738X","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-19T01:06:44.698773Z","pmid":"36669140","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}